Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

The effects of selenium on tumor growth in epithelial ovarian carcinoma.

Park JS, Ryu JY, Jeon HK, Cho YJ, Park YA, Choi JJ, Lee JW, Kim BG, Bae DS.

J Gynecol Oncol. 2012 Jul;23(3):190-6. doi: 10.3802/jgo.2012.23.3.190. Epub 2012 Jul 2.

2.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

3.
4.

Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.

Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK.

Clin Cancer Res. 2005 Jul 1;11(13):4923-33.

5.

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.

Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK.

Clin Cancer Res. 2007 Jun 1;13(11):3423-30.

6.

Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.

Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK.

Clin Cancer Res. 2007 Jul 15;13(14):4209-17.

7.

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK.

Neoplasia. 2008 Nov;10(11):1259-67.

8.

The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.

Clin Cancer Res. 2003 Aug 15;9(9):3476-85.

9.

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

Taylor SA, Marrinan CH, Liu G, Nale L, Bishop WR, Kirschmeier P, Liu M, Long BJ.

Gynecol Oncol. 2008 Apr;109(1):97-106. doi: 10.1016/j.ygyno.2007.12.013. Epub 2008 Jan 31.

PMID:
18237771
10.

Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer.

Hahn HS, Lee KH, Lee IH, Lee JH, Whang CS, Jo YW, Kim TJ.

J Gynecol Oncol. 2014 Apr;25(2):130-5. doi: 10.3802/jgo.2014.25.2.130. Epub 2014 Apr 9.

11.

Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model.

Yu HK, Lee HJ, Yun SJ, Lee SJ, Langley RR, Yoon Y, Yi LS, Bae DS, Kim JS, Kim SJ.

Transl Oncol. 2014 Jun 17;7(3):368-76. doi: 10.1016/j.tranon.2014.04.005. eCollection 2014 Jun.

12.

Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.

Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'reilly MS, Fidler IJ, Herbst RS.

Clin Cancer Res. 2004 Dec 15;10(24):8613-9.

13.

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.

Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK.

Cancer Res. 2007 Jan 1;67(1):281-8.

15.

Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.

Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, Charnsangavej C, Wallace S.

Clin Cancer Res. 1999 Apr;5(4):891-7.

16.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

17.
18.

Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.

Vadgama JV, Wu Y, Shen D, Hsia S, Block J.

Anticancer Res. 2000 May-Jun;20(3A):1391-414.

PMID:
10928049
20.

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.

Nguyen DM, Lorang D, Chen GA, Stewart JH 4th, Tabibi E, Schrump DS.

Ann Thorac Surg. 2001 Aug;72(2):371-8; discussion 378-9.

PMID:
11515869
Items per page

Supplemental Content

Write to the Help Desk